The Intracellular Ca2+ Release Channel TRPML1 Regulates Lower Urinary Tract Smooth Muscle Contractility
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Natural Product Modulators of Transient Receptor Potential (TRP) Channels As Potential Cite This: Chem
Chem Soc Rev View Article Online TUTORIAL REVIEW View Journal | View Issue Natural product modulators of transient receptor potential (TRP) channels as potential Cite this: Chem. Soc. Rev., 2016, 45,6130 anti-cancer agents Tiago Rodrigues,a Florian Sieglitza and Gonçalo J. L. Bernardes*ab Treatment of cancer is a significant challenge in clinical medicine, and its research is a top priority in chemical biology and drug discovery. Consequently, there is an urgent need for identifying innovative chemotypes capable of modulating unexploited drug targets. The transient receptor potential (TRPs) channels persist scarcely explored as targets, despite intervening in a plethora of pathophysiological events in numerous diseases, including cancer. Both agonists and antagonists have proven capable of evoking phenotype changes leading to either cell death or reduced cell migration. Among these, natural products entail biologically pre-validated and privileged architectures for TRP recognition. Furthermore, several natural products have significantly contributed to our current knowledge on TRP biology. In this Creative Commons Attribution 3.0 Unported Licence. Tutorial Review we focus on selected natural products, e.g. capsaicinoids, cannabinoids and terpenes, by highlighting challenges and opportunities in their use as starting points for designing natural product- Received 17th December 2015 inspired TRP channel modulators. Importantly, the de-orphanization of natural products as TRP channel DOI: 10.1039/c5cs00916b ligands may leverage their exploration as viable strategy for developing anticancer therapies. Finally, we foresee that TRP channels may be explored for the selective pharmacodelivery of cytotoxic payloads to www.rsc.org/chemsocrev diseased tissues, providing an innovative platform in chemical biology and molecular medicine. -
The Intracellular Ca2+ Release Channel TRPML1 Regulates Lower Urinary Tract Smooth Muscle Contractility
The intracellular Ca2+ release channel TRPML1 regulates lower urinary tract smooth muscle contractility Caoimhin S. Griffina, Michael G. Alvaradoa, Evan Yamasakia, Bernard T. Drummb,c, Vivek Krishnana, Sher Alia, Eleanor M. Naglea, Kenton M. Sandersb, and Scott Earleya,1 aDepartment of Pharmacology, Center for Molecular and Cellular Signaling in the Cardiovascular System, Reno School of Medicine, University of Nevada, Reno, NV 89557-0318; bDepartment of Physiology and Cell Biology, Reno School of Medicine, University of Nevada, Reno, NV 89557-0318; and cDepartment of Life & Health Sciences, Dundalk Institute of Technology, Louth, Ireland A91 K584 Edited by Mark T. Nelson, University of Vermont, Burlington, VT, and approved October 13, 2020 (received for review August 12, 2020) TRPML1 (transient receptor potential mucolipin 1) is a Ca2+-perme- including dense granulomembranous storage bodies in neurons, able, nonselective cation channel that is predominantly localized to elevated plasma gastrin, vacuolization in the gastric mucosa, and the membranes of late endosomes and lysosomes (LELs). Intracellular retinal degeneration (14). Interestingly, however, an anatomical release of Ca2+ through TRPML1 is thought to be pivotal for mainte- examination of these mice reveals dramatically distended bladders nance of intravesicular acidic pH as well as the maturation, fusion, and (14), leading us to question how TRPML1, an intracellular Ca2+-re- trafficking of LELs. Interestingly, genetic ablation of TRPML1 in mice lease channel important in LEL function, affects bladder physiology. −/− (Mcoln1 ) induces a hyperdistended/hypertrophic bladder phenotype. The lower urinary tract (LUT) is composed of the urinary Here, we investigated this phenomenon further by exploring an un- bladder and urethra—structures that serve the simple, reciprocal conventional role for TRPML1 channels in the regulation of Ca2+-signal- functions of storing and voiding urine (15). -
Recessive Mutations of the Gene TRPM1 Abrogate on Bipolar Cell Function and Cause Complete Congenital Stationary Night Blindness in Humans
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector REPORT Recessive Mutations of the Gene TRPM1 Abrogate ON Bipolar Cell Function and Cause Complete Congenital Stationary Night Blindness in Humans Zheng Li,1 Panagiotis I. Sergouniotis,1 Michel Michaelides,1,2 Donna S. Mackay,1 Genevieve A. Wright,2 Sophie Devery,2 Anthony T. Moore,1,2 Graham E. Holder,1,2 Anthony G. Robson,1,2 and Andrew R. Webster1,2,* Complete congenital stationary night blindness (cCSNB) is associated with loss of function of rod and cone ON bipolar cells in the mammalian retina. In humans, mutations in NYX and GRM6 have been shown to cause the condition. Through the analysis of a consan- guineous family and screening of nine additional pedigrees, we have identified three families with recessive mutations in the gene TRPM1 encoding transient receptor potential cation channel, subfamily M, member 1, also known as melastatin. A number of other variants of unknown significance were found. All patients had myopia, reduced central vision, nystagmus, and electroretinographic evidence of ON bipolar cell dysfunction. None had abnormalities of skin pigmentation, although other skin conditions were reported. RNA derived from human retina and skin was analyzed and alternate 50 exons were determined. The most 50 exon is likely to harbor an initiation codon, and the protein sequence is highly conserved across vertebrate species. These findings suggest an important role of this specific cation channel for the normal function of ON bipolar cells in the human retina. Congenital stationary night blindness (CSNB) is a group of of the gene encoding transient receptor potential cation genetically determined, nondegenerative disorders of the channel, subfamily M, member 1 (TRPM1 [MIM *603576]) retina associated with lifelong deficient vision in the dark has been discovered in the skin and retina of horses homo- and often nystagmus and myopia. -
TRPC1 Antibody Affinity Purified Polyclonal Antibody Catalog # AG1458
9765 Clairemont Mesa Blvd, Suite C San Diego, CA 92124 Tel: 858.875.1900 Fax: 858.622.0609 TRPC1 Antibody Affinity purified polyclonal antibody Catalog # AG1458 Specification TRPC1 Antibody - Product Information Application WB, IHC Primary Accession P48995 Reactivity Human, Mouse, Rat Host Rabbit Clonality Polyclonal Calculated MW 91212 Homology Mouse, rat, human - identical; rabbit, bovine - 14/15 amino acid residues identical; Western blot analysis of rat brain Xenopus Laevis - membranes: 11/14 amino acid 1. Anti-TRPC1 antibody (#AG1458), (1:200). residues identical. 2. Anti-TRPC1 antibody, preincubated with the control peptide antigen. TRPC1 Antibody - Additional Information Gene ID 7220 Other Names Short transient receptor potential channel 1, TrpC1, Transient receptor protein 1, TRP-1, TRPC1, TRP1 Related products for control experiments Control peptide antigen (supplied with the antibody free of charge). Target/Specificity Peptide QLYDKGYTSKEQKDC, corresponding to amino acid residues 557-571 of human .TRPC1 (Accession P48995).ֲ ֲ Intracellular Expression of TRPC1 in mouse cerebellum Immunohistochemical staining of mouse Dilution WB~~1:200-1:2000 cerebellum frozen sections using Anti-TRPC1 antibody (#AG1458). A. TRPC1 (red) appears in Peptide Confirmation Purkinje cells (arrows) and in the molecular Confirmed by amino acid analysis and (Mol) and granule (Gran) layers. B. Staining massspectrography. with mouse anti-parvalbumin (PV) in the same brain section. C. Confocal merge of TRPC1 and Application Details PV demonstrates partial co-localization in the Western blot analysis (WB): - Mouse brain Purkinje and the molecular layers. lysate (see Feng, S. <em>et al.</em> (2013) in Product Citations). - Rat distal pulmonary smooth muscle cell lysate (PASMCs), (see TRPC1 Antibody - Background Zhang, Y. -
Endolysosomal Cation Channels As Therapeutic Targets—Pharmacology of TRPML Channels
Review Copyright © 2016 American Scientific Publishers MESSENGER Vol. 5, 30–36, 2016 All rights reserved www.aspbs.com/messenger Printed in the United States of America Endolysosomal Cation Channels as Therapeutic Targets—Pharmacology of TRPML Channels Christian Grimm Munich Center for Integrated Protein Science CIPSM and Department of Pharmacy-Center for Drug Research, Ludwig-Maximilians-Universität München, 81377, Germany In recent years it has become more and more accepted that the endolysosomal system (ES) plays a key role for human health. Dysfunction of the ES has been found to be implicated in a range of human diseases ranging MESSENGER from infectious and metabolic to lysosomal storage, retinal and neurodegenerative diseases. Results obtained from animal models and human mutations have also spurred the interest in endolysosomal membrane proteins. In particular, the study of endolysosomal ion channels as potential novel drug targets for the treatment of various diseases has gained momentum with recently established endolysosomal patch-clamp techniques. These tech- niques now allow functional characterization of these organellar membrane proteins in more detail. Another key development was the discovery of small molecule agonists and antagonists to pharmacologically interfere with these endolysosomal ion channels in vitro and in vivo. This review gives an overview of the currently available small molecule agonists and antagonists of one major group of endolysosomal cation channels, the mucolipins or TRPML channels and how they have helped to speed up research in the field. Keywords: Calcium, TRPML, MCOLN, TRPML1, Mucolipin. MESSENGER MESSENGER IP: 192.168.39.151 On: Thu, 30 Sep 2021 22:36:36 Copyright: American Scientific Publishers CONTENTS Delivered byand Ingenta neurodegenerative diseases, retinal and pigmentation disorders, trace metal dishomeostasis and infectious dis- Introduction ............................................30 eases (Fig. -
The “Sweet” Side of Ion Channels
Rev Physiol Biochem Pharmacol (2014) 167: 67–114 DOI: 10.1007/112_2014_20 © Springer-Verlag Berlin Heidelberg 2014 Published online: 20 September 2014 The “Sweet” Side of Ion Channels Joanna Lazniewska and Norbert Weiss Abstract Ion channels play a crucial role in cell functioning, contributing to transmembrane potential and participating in cell signalling and homeostasis. To fulfil highly specialised functions, cells have developed various mechanisms to regulate channel expression and activity at particular subcellular loci, and alteration of ion channel regulation can lead to serious disorders. Glycosylation, one of the most common forms of co- and post-translational protein modification, is rapidly emerging as a fundamental mechanism not only controlling the proper folding of nascent channels but also their subcellular localisation, gating and function. More- over, studies on various channel subtypes have revealed that glycosylation repre- sents an important determinant by which other signalling pathways modulate channel activity. The discovery of detailed mechanisms of regulation of ion chan- nels by glycosylation provides new insights in the physiology of ion channels and may allow developing new pharmaceutics for the treatment of ion channel-related disorders. Keywords Ion channel • N-linked glycosylation • O-linked glycosylation • Glycan • Protein glycosylation Contents 1 Introduction ................................................................................... 69 2 Protein Glycosylation in a Nutshell ......................................................... -
Note: the Letters 'F' and 'T' Following the Locators Refers to Figures and Tables
Index Note: The letters ‘f’ and ‘t’ following the locators refers to figures and tables cited in the text. A Acyl-lipid desaturas, 455 AA, see Arachidonic acid (AA) Adenophostin A, 71, 72t aa, see Amino acid (aa) Adenosine 5-diphosphoribose, 65, 789 AACOCF3, see Arachidonyl trifluoromethyl Adlea, 651 ketone (AACOCF3) ADP, 4t, 10, 155, 597, 598f, 599, 602, 669, α1A-adrenoceptor antagonist prazosin, 711t, 814–815, 890 553 ADPKD, see Autosomal dominant polycystic aa 723–928 fragment, 19 kidney disease (ADPKD) aa 839–873 fragment, 17, 19 ADPKD-causing mutations Aβ, see Amyloid β-peptide (Aβ) PKD1 ABC protein, see ATP-binding cassette protein L4224P, 17 (ABC transporter) R4227X, 17 Abeele, F. V., 715 TRPP2 Abbott Laboratories, 645 E837X, 17 ACA, see N-(p-amylcinnamoyl)anthranilic R742X, 17 acid (ACA) R807X, 17 Acetaldehyde, 68t, 69 R872X, 17 Acetic acid-induced nociceptive response, ADPR, see ADP-ribose (ADPR) 50 ADP-ribose (ADPR), 99, 112–113, 113f, Acetylcholine-secreting sympathetic neuron, 380–382, 464, 534–536, 535f, 179 537f, 538, 711t, 712–713, Acetylsalicylic acid, 49t, 55 717, 770, 784, 789, 816–820, Acrolein, 67t, 69, 867, 971–972 885 Acrosome reaction, 125, 130, 301, 325, β-Adrenergic agonists, 740 578, 881–882, 885, 888–889, α2 Adrenoreceptor, 49t, 55, 188 891–895 Adult polycystic kidney disease (ADPKD), Actinopterigy, 223 1023 Activation gate, 485–486 Aframomum daniellii (aframodial), 46t, 52 Leu681, amino acid residue, 485–486 Aframomum melegueta (Melegueta pepper), Tyr671, ion pathway, 486 45t, 51, 70 Acute myeloid leukaemia and myelodysplastic Agelenopsis aperta (American funnel web syndrome (AML/MDS), 949 spider), 48t, 54 Acylated phloroglucinol hyperforin, 71 Agonist-dependent vasorelaxation, 378 Acylation, 96 Ahern, G. -
TRP CHANNELS AS THERAPEUTIC TARGETS TRP CHANNELS AS THERAPEUTIC TARGETS from Basic Science to Clinical Use
TRP CHANNELS AS THERAPEUTIC TARGETS TRP CHANNELS AS THERAPEUTIC TARGETS From Basic Science to Clinical Use Edited by ARPAD SZALLASI MD, PHD Department of Pathology, Monmouth Medical Center, Long Branch, NJ, USA AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier Academic Press is an imprint of Elsevier 125 London Wall, London, EC2Y 5AS, UK 525 B Street, Suite 1800, San Diego, CA 92101-4495, USA 225 Wyman Street, Waltham, MA 02451, USA The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK First published 2015 Copyright © 2015 Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and our arrangement with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein). Notices Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary. Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. -
Snapshot: Mammalian TRP Channels David E
SnapShot: Mammalian TRP Channels David E. Clapham HHMI, Children’s Hospital, Department of Neurobiology, Harvard Medical School, Boston, MA 02115, USA TRP Activators Inhibitors Putative Interacting Proteins Proposed Functions Activation potentiated by PLC pathways Gd, La TRPC4, TRPC5, calmodulin, TRPC3, Homodimer is a purported stretch-sensitive ion channel; form C1 TRPP1, IP3Rs, caveolin-1, PMCA heteromeric ion channels with TRPC4 or TRPC5 in neurons -/- Pheromone receptor mechanism? Calmodulin, IP3R3, Enkurin, TRPC6 TRPC2 mice respond abnormally to urine-based olfactory C2 cues; pheromone sensing 2+ Diacylglycerol, [Ca ]I, activation potentiated BTP2, flufenamate, Gd, La TRPC1, calmodulin, PLCβ, PLCγ, IP3R, Potential role in vasoregulation and airway regulation C3 by PLC pathways RyR, SERCA, caveolin-1, αSNAP, NCX1 La (100 µM), calmidazolium, activation [Ca2+] , 2-APB, niflumic acid, TRPC1, TRPC5, calmodulin, PLCβ, TRPC4-/- mice have abnormalities in endothelial-based vessel C4 i potentiated by PLC pathways DIDS, La (mM) NHERF1, IP3R permeability La (100 µM), activation potentiated by PLC 2-APB, flufenamate, La (mM) TRPC1, TRPC4, calmodulin, PLCβ, No phenotype yet reported in TRPC5-/- mice; potentially C5 pathways, nitric oxide NHERF1/2, ZO-1, IP3R regulates growth cones and neurite extension 2+ Diacylglycerol, [Ca ]I, 20-HETE, activation 2-APB, amiloride, Cd, La, Gd Calmodulin, TRPC3, TRPC7, FKBP12 Missense mutation in human focal segmental glomerulo- C6 potentiated by PLC pathways sclerosis (FSGS); abnormal vasoregulation in TRPC6-/- -
Elevated MCOLN1 Expression in P53-Deficient Bladder Cancer Is Necessary for Oncogene-Induced Cell Proliferation, Inflammation
bioRxiv preprint doi: https://doi.org/10.1101/2020.07.08.193862; this version posted July 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Elevated MCOLN1 Expression in p53-Deficient Bladder Cancer is Necessary for Oncogene-Induced Cell proliferation, Inflammation, and Invasion Jewon Jung1, Han Liao1, Hong Liang1, John F. Hancock1,2, Catherine Denicourt1,2, and Kartik Venkatachalam1,2,3,4,5 1Department of Integrative Biology and Pharmacology, McGovern Medical School at the University of Texas Health Sciences Center (UTHealth), Houston, TX 77030, USA 2Graduate Program in Biochemistry and Cell Biology, MD Anderson Cancer Center and UTHealth Graduate School of Biomedical Sciences 3Graduate Program in Neuroscience, MD Anderson Cancer Center and UTHealth Graduate School of Biomedical Sciences 4Lead Contact 5Correspondence: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2020.07.08.193862; this version posted July 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Summary Inhibition of the endolysosomal cation channel, TRPML1, which is encoded by MCOLN1, deters the proliferation of cancer cells with augmented TFEB activity. Here, we report that the tumor suppressor, p53, antagonizes TFEB-driven MCOLN1 expression in bladder cancer. -
Neuropathophysiology, Genetic Profile, and Clinical Manifestation of Mucolipidosis IV—A Review and Case Series
International Journal of Molecular Sciences Review Neuropathophysiology, Genetic Profile, and Clinical Manifestation of Mucolipidosis IV—A Review and Case Series 1, 2, 3, , Aleksandra Jezela-Stanek y , El˙zbietaCiara y and Karolina M. Stepien * y 1 Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland; [email protected] 2 Department of Medical Genetics, The Children’s Memorial Heath Institute, 04-730 Warsaw, Poland; [email protected] 3 Adult Inherited Metabolic Diseases, Salford Royal NHS Foundation Trust, Salford M6 8HD, UK * Correspondence: [email protected] These authors contributed equally to this work. y Received: 31 May 2020; Accepted: 23 June 2020; Published: 26 June 2020 Abstract: Mucolipidosis type IV (MLIV) is an ultra-rare lysosomal storage disorder caused by biallelic mutations in MCOLN1 gene encoding the transient receptor potential channel mucolipin-1. So far, 35 pathogenic or likely pathogenic MLIV-related variants have been described. Clinical manifestations include severe intellectual disability, speech deficit, progressive visual impairment leading to blindness, and myopathy. The severity of the condition may vary, including less severe psychomotor delay and/or ocular findings. As no striking recognizable facial dysmorphism, skeletal anomalies, organomegaly, or lysosomal enzyme abnormalities in serum are common features of MLIV, the clinical diagnosis may be significantly improved because of characteristic ophthalmological anomalies. This review aims to outline the pathophysiology and genetic defects of this condition with a focus on the genotype–phenotype correlation amongst cases published in the literature. The authors will present their own clinical observations and long-term outcomes in adult MLIV cases. -
Download File
STRUCTURAL AND FUNCTIONAL STUDIES OF TRPML1 AND TRPP2 Nicole Marie Benvin Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2017 © 2017 Nicole Marie Benvin All Rights Reserved ABSTRACT Structural and Functional Studies of TRPML1 and TRPP2 Nicole Marie Benvin In recent years, the determination of several high-resolution structures of transient receptor potential (TRP) channels has led to significant progress within this field. The primary focus of this dissertation is to elucidate the structural characterization of TRPML1 and TRPP2. Mutations in TRPML1 cause mucolipidosis type IV (MLIV), a rare neurodegenerative lysosomal storage disorder. We determined the first high-resolution crystal structures of the human TRPML1 I-II linker domain using X-ray crystallography at pH 4.5, pH 6.0, and pH 7.5. These structures revealed a tetramer with a highly electronegative central pore which plays a role in the dual Ca2+/pH regulation of TRPML1. Notably, these physiologically relevant structures of the I-II linker domain harbor three MLIV-causing mutations. Our findings suggest that these pathogenic mutations destabilize not only the tetrameric structure of the I-II linker, but also the overall architecture of full-length TRPML1. In addition, TRPML1 proteins containing MLIV- causing mutations mislocalized in the cell when imaged by confocal fluorescence microscopy. Mutations in TRPP2 cause autosomal dominant polycystic kidney disease (ADPKD). Since novel technological advances in single-particle cryo-electron microscopy have now enabled the determination of high-resolution membrane protein structures, we set out to solve the structure of TRPP2 using this technique.